(Q35959046)

English

What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment?

scientific article published on 10 April 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

7 references

13 March 2019

14 March 2019

24 March 2019

17 June 2019

2 October 2019

29 May 2020

31 August 2020

What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment? (English)

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

arterial hypertension

7 references

13 March 2019

14 March 2019

24 March 2019

17 June 2019

2 October 2019

29 May 2020

31 August 2020

mechanism of action

1 reference

2 October 2019

diabetic nephropathy

1 reference

31 August 2020

author name string

Samir G Mallat

1

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

language of work or name

0 references

publication date

10 April 2012

7 references

Europe PubMed Central

PMC publication ID

11 August 2017

13 March 2019

14 March 2019

24 March 2019

17 June 2019

2 October 2019

31 August 2020

Cardiovascular Diabetology

7 references

Europe PubMed Central

PMC publication ID

11 August 2017

13 March 2019

14 March 2019

24 March 2019

17 June 2019

2 October 2019

31 August 2020

11

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

32

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

copyright license

Creative Commons Attribution 2.0 Generic

6 references

Europe PubMed Central

13 March 2019

Europe PubMed Central

14 March 2019

Europe PubMed Central

24 March 2019

Europe PubMed Central

17 June 2019

Europe PubMed Central

2 October 2019

Europe PubMed Central

31 August 2020

copyright status

0 references

on focus list of Wikimedia project

0 references

Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Efficacy of renin-angiotensin system (RAS) blockers on cardiovascular and renal outcomes in patients with type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: a retrospective observational study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Role of aliskiren in blood pressure control and renoprotection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Value of Angiotensin receptor blocker therapy in diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Renal protection in diabetes: lessons from ONTARGET.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Effect of candesartan monotherapy on lipid metabolism in patients with hypertension: a retrospective longitudinal survey using data from electronic medical records

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

New standards in hypertension and cardiovascular risk management: focus on telmisartan

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Telmisartan: a different angiotensin II receptor blocker protecting a different population?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Valsartan: more than a decade of experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Clinical experience in treating hypertension with fixed-dose combination therapy: angiotensin II receptor blocker losartan plus hydrochlorothiazide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: an emerging strategy in hypertension therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin-angiotensin system

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Fixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of the olmesartan-amlodipine combination

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Managing hypertension using combination therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Telmisartan, ramipril, or both in patients at high risk for vascular events

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Association of cardiovascular risk factors with microalbuminuria in hypertensive individuals: the i-SEARCH global study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Maximising antihypertensive effects of angiotensin II receptor blockers with thiazide diuretic combination therapy: focus on irbesartan/hydrochlorothiazide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Fixed-dose combinations improve medication compliance: a meta-analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Trends in hypertension prevalence, awareness, treatment, and control in older U.S. adults: data from the National Health and Nutrition Examination Survey 1988 to 2004.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

The effect of telmisartan and ramipril on early morning blood pressure surge: a pooled analysis of two randomized clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Angiotensin-receptor blocking agents and the peroxisome proliferator-activated receptor-gamma system

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Antihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Calcium channel blockers, postural vasoconstriction and dependent oedema in essential hypertension

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Cardiac and vascular remodelling: effect of antihypertensive agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Quality of life in the treatment of hypertension. The effect of calcium antagonists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

2 October 2017

Urinary albumin excretion during angiotensin II receptor blockade: comparison of combination treatment with a diuretic or a calcium-channel blocker

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

11 July 2018

Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians' Desk Reference

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

11 July 2018

Results of treatment with telmisartan-amlodipine in hypertensive patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

11 July 2018

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

11 July 2018

The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

11 July 2018

Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

11 July 2018

The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

11 July 2018

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

11 July 2018

Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

11 July 2018

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

11 July 2018

A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

11 July 2018

Trends and cardiovascular mortality effects of state-level blood pressure and uncontrolled hypertension in the United States

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

Management of hypertension: summary of NICE guidance

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

Adherence and persistence of single-pill ARB/CCB combination therapy compared to multiple-pill ARB/CCB regimens.

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

Predictors of hyperkalemia risk following hypertension control with aldosterone blockade

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 x 4 factorial study

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

Comparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVERESTE study

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-gro

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

Sustained antihypertensive activity of telmisartan compared with valsartan

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

Comparison of the effects of telmisartan and olmesartan on home blood pressure, glucose, and lipid profiles in patients with hypertension, chronic heart failure, and metabolic syndrome

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

Evaluating 24-h antihypertensive efficacy by the smoothness index: a meta-analysis of an ambulatory blood pressure monitoring database

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapy

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

Telmisartan/Hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertension

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

Impact of angiotensin receptor blockade in combination with hydrochlorothiazide 25 mg in 2121 patients with stage 1-2 hypertension

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults wit

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

Safety and tolerability of fixed-dose irbesartan/hydrochlorothiazide for rapid control of severe hypertension

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

24-hour ambulatory blood pressure in the ACCOMPLISH trial

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

Single-pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized, parallel-group, double-blind trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

24 September 2018

Combination therapy in hypertension

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

24 September 2018

Blood pressure-lowering and antiproteinuric effect of switching from high-dose angiotensin receptor blockers to normal-dose telmisartan and low-dose hydrochlorothiazide in hypertensive patients with chronic kidney disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

24 September 2018

Effect of telmisartan on renal outcomes: a randomized trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

24 September 2018

The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

24 September 2018

Standards of medical care in diabetes--2008.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

24 September 2018

Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

24 September 2018

Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

24 September 2018

Telmisartan in patients with mild/moderate hypertension and chronic kidney disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

24 September 2018

The efficacy of telmisartan compared with perindopril in patients with mild-to-moderate hypertension.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

24 September 2018

A double-blind ambulatory blood pressure monitoring study of the efficacy and tolerability of once-daily telmisartan 40 mg in comparison with losartan 50 mg in the treatment of mild-to-moderate hypertension in Taiwanese patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351968

24 September 2018

Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

2007 Guidelines for the Management of Arterial Hypertension

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials

1 reference

https://api.crossref.org/works/10.1186%2F1475-2840-11-32

21 January 2018

Efficacy and tolerability of telmisartan plus amlodipine in added-risk hypertensive patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/22490507

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertension

1 reference

https://pubmed.ncbi.nlm.nih.gov/22490507

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Angiotensin-converting enzyme inhibitors and angioedema: estimating the risk

1 reference

https://pubmed.ncbi.nlm.nih.gov/22490507

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22490507

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22490507

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema

1 reference

https://pubmed.ncbi.nlm.nih.gov/22490507

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008

1 reference

https://pubmed.ncbi.nlm.nih.gov/22490507

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009)

1 reference

https://pubmed.ncbi.nlm.nih.gov/22490507

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22490507

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/22490507

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control

1 reference

https://pubmed.ncbi.nlm.nih.gov/22490507

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1475-2840-11-32

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35959046&oldid=2198000167"